A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)

Targacept

Status and phase

Completed

Phase 2

Conditions

Age-Related Memory Disorders

Treatments

Drug: ispronicline (nicotinic acetylcholine receptor agonist)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00109564

TC-1734-112-CRD-004

Details and patient eligibility

About

The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging.

Sex

All

Ages

50 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Male or female subjects aged 50-80 years.
Lives with a significant other.
Has subjective memory complaints. Verbal verification of this subjective memory complaint will be obtained from the significant other.
Has no severe, uncontrolled medical condition.
If receiving treatment for a medical condition, that treatment has been stable for at least 2 months before entering the trial and to remain stable throughout the trial.

Exclusion Criteria

Aged less than 50 years or greater than 80 years.
Lives alone.
Has any medical condition not adequately controlled, or likely to interfere with performance of the study procedures.
Medication for a medical condition has been changed in the last 2 months or during the trial.
Administration of acetylcholinesterase inhibitors and gingko biloba within 2 months prior to entering the study.
Has evidence of depression or anxiety
Meets DSM-IV criteria for Alzheimer's or vascular dementia.
Has participated in an investigational drug trial in the previous 30 days.